免疫疗法
免疫系统
细胞毒性T细胞
抗原
癌症免疫疗法
免疫学
获得性免疫系统
CD8型
抗体
先天免疫系统
医学
肿瘤抗原
T细胞
生物
癌症研究
免疫检查点
体外
生物化学
作者
Kelly D. Moynihan,Cary F. Opel,Gregory L. Szeto,Alice Tzeng,Eric F. Zhu,J Engreitz,Robert T. Williams,Kavya Rakhra,Michael H. Zhang,Adrienne M. Rothschilds,Sudha Kumari,Ryan L. Kelly,Byron H. Kwan,Wuhbet Abraham,Kevin Hu,Naveen K. Mehta,Monique J. Kauke,Heikyung Suh,Jennifer R. Cochran,Douglas A. Lauffenburger,K. Dane Wittrup,Darrell J. Irvine
出处
期刊:Nature Medicine
[Springer Nature]
日期:2016-10-24
卷期号:22 (12): 1402-1410
被引量:456
摘要
An immunotherapy consisting of a tumor-antigen targeting antibody, PD-1 blocking antibody, extended half-life recombinant IL-2 and a lymph-node-targeted T cell vaccine mobilized innate and adaptive immunity and eradicated large established tumors in a variety of mouse models. Checkpoint blockade with antibodies specific for cytotoxic T lymphocyte–associated protein (CTLA)-4 or programmed cell death 1 (PDCD1; also known as PD-1) elicits durable tumor regression in metastatic cancer, but these dramatic responses are confined to a minority of patients. This suboptimal outcome is probably due in part to the complex network of immunosuppressive pathways present in advanced tumors, which are unlikely to be overcome by intervention at a single signaling checkpoint. Here we describe a combination immunotherapy that recruits a variety of innate and adaptive immune cells to eliminate large tumor burdens in syngeneic tumor models and a genetically engineered mouse model of melanoma; to our knowledge tumors of this size have not previously been curable by treatments relying on endogenous immunity. Maximal antitumor efficacy required four components: a tumor-antigen-targeting antibody, a recombinant interleukin-2 with an extended half-life, anti-PD-1 and a powerful T cell vaccine. Depletion experiments revealed that CD8+ T cells, cross-presenting dendritic cells and several other innate immune cell subsets were required for tumor regression. Effective treatment induced infiltration of immune cells and production of inflammatory cytokines in the tumor, enhanced antibody-mediated tumor antigen uptake and promoted antigen spreading. These results demonstrate the capacity of an elicited endogenous immune response to destroy large, established tumors and elucidate essential characteristics of combination immunotherapies that are capable of curing a majority of tumors in experimental settings typically viewed as intractable.
科研通智能强力驱动
Strongly Powered by AbleSci AI